Ther FINANCAIL -- Helix BioPharma Corp., a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that the "clinical hold" on its investigational new drug  application for its Topical Interferon Alpha-2b, Phase II/III, low-grade cervical lesion efficacy trial has been removed by the United States Food and Drug Administration .

The FDA completed its review of Helix's "clinical hold" complete response submission, which Helix filed as announced in its news release of October 12, 2011, and granted Helix approval to perform the planned clinical trial.

The Company is still in need of additional funding as well as strategic partner support before commencing this trial. As such, it does not currently have an estimated timeline for commencement or completion of this trial. The Company hopes, however, that this FDA approval will be helpful in generating the support it requires.

Related Stories

• Innovative public-private collaboration launches to tackle antibiotic research
• Phase II Trial Used Ambulatory Blood Pressure Monitoring to Evaluate Blood Pressure
• Pharmacyclics Announces Oral Presentations of Ibrutinib